Conference 2021 Live Talk


Talk title

LncRNA LINC00511 from newly diagnosed Egyptian breast cancer patients: A tale of a promising diagnostic molecular biomarker


Authors and Affiliations

Marwa M. Mahmoud1, Eman F. Sanad1, Reham A.A. Elshimy2, Nadia M. Hamdy1

1. Biochemistry Department, Faculty of Pharmacy, Ain Shams University, 11566, Cairo, Egypt
2. Clinical and Chemical Pathology Department, National Cancer Institute, Cairo University, Cairo, Egypt




Among Egyptian females, breast cancer (BC) is the leading cause of cancer related mortalities. Recently, emerging evidence has illustrated the vital role of long non-coding RNAs (lncRNAs) as promising pool of regulators for tuning the aggressiveness of several solid malignancies. However, this still needs further investigations regarding Egyptian BC patients. This research aims to unravel the expression pattern and to put emphasis on the diagnostic value of the long intergenic non-protein coding RNA00511 (LINC00511) in newly diagnosed Egyptian female BC patients.


LINC00511 was chosen from database then validation and molecular binding were confirmed using bioinformatics analysis. LINC00511 expression was measured in healthy (20) and naïve BC patients (70) using qRT-PCR. The association between LINC00511 expression and clinicopathological features was assessed as well as the receiver operating characteristic (ROC) curve was blotted to determine the best cutoff point that discriminates between cancer and noncancer groups. The best cutoff point was used to calculate sensitivities and specificities for LINC00511, to weigh out its diagnostic efficacy over other classical protein biomarkers, namely CA15.3 or CEA.


LINC00511 was highly expressed in the BC patients when compared to controls (5.282± 1.206 vs. 0.9401± 0.1949, respectively, at P <0.0001). LINC00511 levels were correlated with BC risk factors, clinicopathological and demographic factors. Additionally, LINC00511 levels were positively correlated with the aggressiveness of the disease as manifested in patients with larger tumor volume (>5 mm3, P <0.0037), lymph-node metastasis (P <0.0001) and advanced tumor grade (P <0.0155). LINC00511 was found to be elevated in progressing late-stage BC patients when compared to early-stages (P <0.0079). LINC00511 showed AUC equals 0.970 (95% CI, 0.881 to 0.998, P <0.0001) being superior to conventional tumor markers.


Our data highlights LINC00511 pivotal role for diagnosis as well as in determining aggressiveness of BC. Representing a novel, promising diagnostic molecular biomarker for BC patients, LINC00511 might play part in BC pathogenesis and/or progression either alone or in association with microRNAs as miR-185-3p or miR-301a; suggested by bioinformatics, are now studied by our group. And, to get the complete picture, we currently started to study LINC00511 SNPs in BC as well.